Last update 01 Nov 2024
Sino-American Shanghai Squibb Pharmaceuticals Ltd.

Sino-American Shanghai Squibb Pharmaceuticals Ltd.

Joint Venture Company|
1982|
Shanghai Shi, China
|
www.bms.com

Overview

Tags

Neoplasms
Hemic and Lymphatic Diseases
Immune System Diseases
Small molecule drug
Monoclonal antibody
Autologous CAR-T

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms21
Hemic and Lymphatic Diseases18
Immune System Diseases18
Infectious Diseases7
Endocrinology and Metabolic Disease5
Nervous System Diseases5
Top 5 Drug TypeCount
Small molecule drug18
Monoclonal antibody8
Autologous CAR-T2
Antibody drug conjugate (ADC)1
NK cell engagers (NKCE)1
Top 5 TargetCount
BET(Bromodomain and extra terminal domain protein)2
CRBN x Ubiquitin-protein ligases1
BTK(Tyrosine-protein kinase BTK)1
LAG3 x PD-11
HDACs(Histone deacetylase)1

Related

34
Drugs associated with Sino-American Shanghai Squibb Pharmaceuticals Ltd.
Nivolumab/Relatlimab
Target
LAG3 x PD-1
Mechanism
LAG3 inhibitors [+1]
Active Org.
Bristol Myers Squibb Co.Bristol Myers Squibb Co. [+5]
Originator Org.
Bristol Myers Squibb Co.Bristol Myers Squibb Co.
Active Indication
Metastatic melanoma [+7]
Inactive Indication
HER2 negative Gastroesophageal Junction Adenocarcinoma [+2]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date18 Mar 2022
Idecabtagene Vicleucel
Target
BCMA
Mechanism
BCMA inhibitors
Active Org.
Bristol-Myers Squibb Pharma EEIG [+6]
Originator Org.
bluebird bio, Inc.bluebird bio, Inc.
Active Indication
Multiple Myeloma [+1]
Inactive Indication
BCMA Positive Multiple Myeloma
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date03 Mar 2021
Fedratinib Hydrochloride
Target
FLT3 x JAK2
Mechanism
FLT3 inhibitors [+1]
Active Org.
Bristol Myers Squibb Co.Bristol Myers Squibb Co. [+3]
Originator Org.
TargeGen, Inc.TargeGen, Inc.
Active Indication
Post-essential thrombocythemia myelofibrosis [+12]
Inactive Indication
Blast Phase Chronic Granulocytic Leukemia [+2]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date16 Aug 2019
4
Clinical Trials associated with Sino-American Shanghai Squibb Pharmaceuticals Ltd.
CTR20200530 / CompletedNot Applicable
一项在健康中国参加者中评估中国产与意大利产福辛普利钠片生物等效性的单剂量、开放性、随机、双向交叉研究
[Translation] A single-dose, open-label, randomized, two-way crossover study to evaluate the bioequivalence of Chinese-made and Italian-made fosinopril sodium tablets in healthy Chinese participants
CTR20191248 / Active, not recruiting
一项在健康中国参加者中评估中国产与意大利产 Monopril (10 mg) 片剂生物等效性的单剂量、开放性、随机、双向交叉研究
[Translation] A single-dose, open-label, randomized, two-way crossover study to evaluate the bioequivalence of Chinese and Italian Monopril (10 mg) tablets in healthy Chinese participants
CTR20171603 / Completed
评估两组健康受试者于进食和空腹状态下单次服用两种格华止速释片的生物等效性的随机化开放标签双向交叉研究
[Translation] A randomized, open-label, two-way crossover study to evaluate the bioequivalence of two immediate-release Glucophage tablets in two groups of healthy subjects after single administration in the fed and fasted states
100 Clinical Results associated with Sino-American Shanghai Squibb Pharmaceuticals Ltd.
Login to view more data
0 Patents (Medical) associated with Sino-American Shanghai Squibb Pharmaceuticals Ltd.
Login to view more data
100 Deals associated with Sino-American Shanghai Squibb Pharmaceuticals Ltd.
Login to view more data
100 Translational Medicine associated with Sino-American Shanghai Squibb Pharmaceuticals Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 25 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1 Clinical
9
10
Phase 2 Clinical
Phase 3 Clinical
7
6
Approved
Other
2
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free